- Triple-strength Wegovy 'mega dose' given green light by health officials allowing users to shed 'significantly more weight' with a single injection Daily Mail —
- Novo Nordisk teams up with OpenAI to boost AI-driven drug discovery efforts Seeking Alpha —
- UK approves Novo Nordisk single-dose 7.2mg Wegovy pen for obesity patients Seeking Alpha —
- Novo Nordisk and OpenAI Partner to Speed Drug Discovery Wall Street Journal —
- Wegovy major change from April 14 for certain people using jab to lose weight Mirror —
- Novo Nordisk partners with OpenAI as AI drug discovery hopes mount CNBC —
- Five key weight loss jab side effects reported by 43 percent of patients Mirror —
- Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development - Reuters Reuters —
- Popular weight-loss medications linked to hidden side effects, study finds Fox News —
- Novo Taps OpenAI to Speed Development of New Obesity Drugs Bloomberg —
- Study flags unreported GLP-1 side effects in analysis of social media posts CTV News —
- Thousands are sharing side effects of weight-loss drugs doctors may miss, study suggests CTV News —
- Canadian lab explains puzzling link between semaglutide, better liver health The Globe and Mail —
- Breakingviews - Weight loss drugs face first economic stress test - Reuters Reuters —
- Why weight-loss jabs could improve liver health The Independent —
- US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises The Guardian —
Wegovy
Pharmaceutical product
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardiovascular events. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold by Novo Nordisk under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management, weight loss, and the treatment of metabolic-associated steatohepatitis.